The identification of TFEB as the master regulator of lysosomal activity, and the fact that TFEB and other members of the MiT/TFE family are considered oncogenes in several cancers, have highlighted the importance of lysosomes in cancer and underscored its potential as a therapeutic target [50]. This evidence concerns the gene TFEB and cancer.